Bone turnover markers in the management of postmenopausal osteoporosis

Brown, Jacques P.; Albert, Caroline; Nassar, B.A.; Adachi, Jonathan D.; Cole, David E. C.; Davison, K. Shawn; Dooley, Kent C.; Don-Wauchope, Andrew; Douville, Pierre; Hanley, David A.; Jamal, Sophie A.; Josse, Robert G.; Kaiser, Stéphanie; Krahn, John; Krause, Richard; Kremer, Richard; Lepage, Raymond; Letendre, Elaine D.; Morin, Suzanne N; Ooi, Daylily S.; Papaioaonnou, Alexandra; Ste‐Marie, Louis‐Georges

doi:10.1016/j.clinbiochem.2009.04.001

Cited by 180 publications

(180 citation statements)

References 120 publications

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…Bone formation markers include serum bone specific osteocalcin, serum bone specific alkaline phosphatase, serum procollagen type I Nterminal propeptide (PINP) and serum procollagen type I C-terminal propeptide (PICP) (Figure 1; p.39) [97][98][99]. Bone specific alkaline phosphatase has been previously utilized to assess bone formation in metabolic bone diseases where abnormal remodeling occurs [100].…”

Section: Serum and Urinary Bone Turnover Markersmentioning

confidence: 99%

“…On the other hand, bone resorption markers include serum collagen type I Ctelopeptide (sCTX), urinary N-telopeptide of type I collagen (uNTX) and urinary-free deoxypyridoline [10,97]. Although all bone resorption markers can be found in both serum and urine, serum CTX and urine NTX are most commonly used since they tend to be more stable in those forms [106].…”

Section: Serum and Urinary Bone Turnover Markersmentioning

confidence: 99%

“…Although all bone resorption markers can be found in both serum and urine, serum CTX and urine NTX are most commonly used since they tend to be more stable in those forms [106]. Both sCTX and uNTX are type I collagen degradation fragments rendered by bone resorption processes and sCTX has a serum half-life of 5 to 7 days [97]. High levels of either degradation product signals high bone turnover which can denote loss of BMD when not coupled with high bone formation markers [97].…”

Section: Serum and Urinary Bone Turnover Markersmentioning

confidence: 99%

“…Both sCTX and uNTX are type I collagen degradation fragments rendered by bone resorption processes and sCTX has a serum half-life of 5 to 7 days [97]. High levels of either degradation product signals high bone turnover which can denote loss of BMD when not coupled with high bone formation markers [97]. In a recent retrospective study, 315 participants diagnosed with OI were analyzed for 25OHD serum concentrations prior to receiving any bisphosphonate treatment [32].…”

Section: Serum and Urinary Bone Turnover Markersmentioning

confidence: 99%

“…Biochemical bone turnover markers have been used as complimentary tools in assessing bone formation in combination with BMD measurements in numerous studies [10,97,107,108]. A case-control study conducted with adult OI patients showed significant increases in all bone turnover markers studied with the exception of sCTX [98].…”

Section: Serum and Urinary Bone Turnover Markersmentioning

confidence: 99%

See 4 more Smart Citations

Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial

Plante

Veilleux

Glorieux

et al. 2016

Bone

View full text Add to dashboard Cite

Background Osteogenesis imperfecta (OI) is a genetic disease characterized by fragile bones and short stature. Recently, a positive association was found between serum 25‐hydroxyvitamin D (25OHD) concentrations and lumbar spine areal bone mineral density (LS‐aBMD) z‐scores in this population. Objectives: To assess whether high‐dose vitamin D supplementation (2000 IU) will result in significantly higher LS‐aBMD z‐scores after one‐year; and to evaluate the effect of vitamin D supplementation on lower limb muscle power. Results: At baseline, average serum 25OHD concentration was 65.6 nmol/L (SD 20.4) with no difference seen between treatment groups (p=0.77). Deficient serum 25OHD concentrations (<50 nmol/L) were measured in only 21% of patients at baseline. Supplementation resulted in higher serum 25OHD concentrations in almost all participants (90%) with significantly higher increases seen with 2000 IU (mean [95% C.I.] = 30.5 nmol/L [21.3; 39.6] vs 15.2 nmol/L [6.4; 24.1], p= 0.02). No significant changes were detected in BMD measurements or in lower limb muscle power between treatment groups from baseline to final visit. Conclusions Supplementation with either 400 or 2000 IU of vitamin D translates into significant increases in serum 25OHD concentrations in children with OI. However, increases in baseline serum 25OHD concentrations already within a healthy range (蠅50 nmol/L) do not translate into increases in BMD z‐scores in children with OI. This research was supported by the Shriners Hospital for Children as well as by The Network for Oral and Bone Health Research.

show abstract

Section: Serum and Urinary Bone Turnover Markersmentioning

confidence: 99%

Section: Serum and Urinary Bone Turnover Markersmentioning

confidence: 99%

Section: Serum and Urinary Bone Turnover Markersmentioning

confidence: 99%

Section: Serum and Urinary Bone Turnover Markersmentioning

confidence: 99%

Section: Serum and Urinary Bone Turnover Markersmentioning

confidence: 99%

See 3 more Smart Citations

Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial

Plante

Veilleux

Glorieux

et al. 2016

Bone

View full text Add to dashboard Cite

show abstract

Monitoring Therapy for Osteoporosis

Lewiecki

2013

Osteoporosis

View full text Add to dashboard Cite

The effect of whole body vibration therapy on bone density in patients with thalassemia: A pilot study

Fung¹,

Gariepy²,

Sawyer

et al. 2012

American J Hematol

View full text Add to dashboard Cite

Patients with thalassemia (Thal) have low bone mass which can lead to fracture and decreased quality of life. There are no noninvasive anabolic therapies available to improve bone health in Thal. A longitudinal cross-over pilot trial was conducted to evaluate the effectiveness of low magnitude whole body vibration (WBV) therapy on bone in 18 patients with Thal (9 adults, 10 male, 22.1 ± 10.7 years). Subjects were asked to stand on a vibrating platform (30 Hz, 0.3 g) for 20 min/day for 6 months. Areal bone mineral density (aBMD) by DXA and volumetric BMD by peripheral quantitative computed tomography (pQCT) was assessed at baseline, 6 and 12 months. Adherence in the first 3 months was greater when compared with the second 3 months (14 ± 6 vs. 10 ± 7 min/day, P=0.007). Intention to treat analysis revealed a significant increase in whole body BMC (2.6%; P = 0.021), BMC/Ht (2.6%, P = 0.02) and aBMD (1.3%; P = 0.036), as well as a net increase in serum markers of bone formation (Osteocalcin/CTx, P = 0.027) in the adult subjects. These preliminary findings suggest that vibration therapy may be an effective nonpharmacologic intervention in Thal. Future research is needed to confirm these findings in a larger sample for longer duration.

show abstract

Bone turnover markers in the management of postmenopausal osteoporosis

Cited by 180 publications

References 120 publications

Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial

Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial

Monitoring Therapy for Osteoporosis

The effect of whole body vibration therapy on bone density in patients with thalassemia: A pilot study

Contact Info

Product

Resources

About